dard for Radiation Oncology, “The prescription should include: volume
(site) to be treated, description of portals (e.g., AP, PA, lateral, etc.),
radiation modality, dose per fraction, number of fractions per day, num-
ber of fractions per week, total number of fractions, total tumor dose,
and prescription point or isodose.” For patients receiving both external
beam therapy and an implant, all prescriptions should be maintained in
the patient’s chart (ie, a prescription for external beam, as well as one
for each implant). As treatments become more complex and different
fractionation schedules are used, it is not always universally understood
what simple abbreviated prescriptions mean. This necessitates a strict
definition of prescription to minimize the likelihood of error.
2. Portal verification films. According to the ACR Standard for Radi-
ation Oncology, portal verification films should be taken at the begin-
ning of therapy, with field changes, and at least every other week. All
portal verification films should be labeled with the patient’s name, the
date they were taken, the field size, and the direction of the beam; the
label should also include the radiation oncologist’s signature and date
signed. The physician approving simulation or portal verification films
or recommending a change must initial the films and indicate the date
of approval and suggested modification.
3. Physics completion check. According to the ACR Standard for
Radiation Oncology Physics for External Beam Therapy, at the com-
pletion of treatment the radiation oncology physicist shall review,
sign, and date the entire chart to affirm the fulfillment of the initial or
revised prescription dose.
4. Elements of a history and physical examination. All patients who
are evaluated should have a comprehensive history and physical exam-
ination in the chart. This should include a comprehensive history of the
present illness, medical history, review of symptoms, physical exami-
nation, review of imaging studies and laboratory data, histopathologic
data, and diagnosis and recommendations. For example, charts of
patients with breast cancer should include information on pertinent
aspects of breast cancer, such as estrogen and progesterone receptor
status, menopausal status, chemotherapy, and hormone therapy status.
5. Quality assurance for treatment planning system. The quality
assurance plan for each treatment planning system should be formally
documented. The element of periodic confirmation of the treatment
planning system consistency should be included.
6. Brachytherapy documentation. More complete brachytherapy
documentation is recommended. The written directive should include
the treatment site, isotope, number of sources, and the planned dose to
Curr Probl Cancer, March/April 2001
123